Endomyocardial Botulinum Toxin Injection in Patients With Persistent Atrial Fibrillation



Status:Recruiting
Conditions:Atrial Fibrillation
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - 70
Updated:4/21/2016
Start Date:June 2013
End Date:January 2016
Contact:Evgeny Pokushalov, MD, PhD
Email:e.pokushalov@gmail.com
Phone:+79139254858

Use our guide to learn which trials are right for you!

The investigators have conducted a prospective, double-blind, randomized study to assess the
comparative safety and efficacy of two different ablation strategies, PVI plus linear
lesions (LL) plus botulinum toxin injection versus PVI plus linear lesions (LL), in patients
with persistent or longstanding persistent AF. Results were assessed with the use of an
implanted monitoring device (IMD).


Inclusion Criteria:

- Persistent and longstanding persistent AF

Exclusion Criteria:

- congestive heart failure

- LV ejection fraction < 35%

- left atrial diameter > 60 mm
We found this trial at
2
sites
Novosibirsk, 63005
Principal Investigator: Evgeny Pokushalov, MD, PhD
Phone: +79139254858
?
mi
from
Novosibirsk,
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
(585) 275-2121
University of Rochester The University of Rochester is one of the country's top-tier research universities....
?
mi
from
Rochester, NY
Click here to add this to my saved trials